▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #527 by analyst upside · 2026-09-28
NYXH
Nyxoah SA
Healthcare · Market Cap $148M · P/E 0x
ANALYST PRICE TARGET
+194.2%
implied upside to consensus target
Current Price $1.45
Consensus Target $4.27
Bull Target $5.88
Bear Target $2.96
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
2
Sell
0
52-Week Low $1.26
52-Week High $6.88
YTD Return -67.8%
FUNDAMENTALS
Market Cap $148M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $22M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.26
52-Week High $6.88
Current Price $1.45
Bear Target $2.96
Bull Target $5.88
● Now $1.45 ● Target $4.27
TRADING DATA
Avg Volume 286K
YTD Return -67.8%
Analyst Count 3
Consensus Buy
Upside to Target +194.2%
Last Updated 2026-09-28

ANALYST SUMMARY

Nyxoah SA (NYXH) is currently trading at $1.45 with a Wall Street consensus price target of $4.27, implying potential upside of 194.2% over the next 12 months. 3 analysts currently cover NYXH, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.88, while the most cautious has a target of $2.96.

NYXH operates in the Healthcare sector with a market capitalisation of $148M. The stock is down 67.8% year-to-date and is currently trading near the lower end of its 52-week range of $1.26 – $6.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

WW +97.4%
WW International, Inc.
$144M · P/E 1.6x · Hold
CGEN +93.3%
Compugen Ltd.
$225M · P/E 6.3x · Buy
FBIO +119.3%
Fortress Biotech, Inc.
$76M · P/E 0.8x · Buy
SABS +253.7%
SAB Biotherapeutics, Inc.
$299M · P/E 13.7x · Buy
CCLD +257.7%
CareCloud, Inc.
$87M · P/E 29.3x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for NYXH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-08-17 40% win rate (10 calls)
Piper Sandler reit
Overweight → Overweight 2026-08-06 14% win rate (7 calls)
Stifel - Reiterated
Hold → Hold 2026-06-17 Building track record
Piper Sandler reit
Overweight → Overweight 2026-05-13 14% win rate (7 calls)
Stifel ↓ Downgrade
Buy → Hold 2026-05-12 Building track record
Stifel - Reiterated
Buy → Buy 2026-04-10 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2026-03-23 40% win rate (10 calls)
Stifel - Reiterated
Buy → Buy 2026-03-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
18
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →